Akari Therapeutics Plc EV/EBIT
Quel est le EV/EBIT de Akari Therapeutics Plc?
Le EV/EBIT de Akari Therapeutics Plc est N/A
Quelle est la définition de EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT des entreprises dans Health Care secteur sur NASDAQ par rapport à Akari Therapeutics Plc
Que fait Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Entreprises avec ev/ebit similaire à Akari Therapeutics Plc
- Canadian General Investments a EV/EBIT de N/A
- Omnia Metals Ltd a EV/EBIT de N/A
- Netgear Inc a EV/EBIT de N/A
- Vroom a EV/EBIT de N/A
- OncoSec Medical Inc a EV/EBIT de N/A
- Hemogenyx Pharmaceuticals Plc a EV/EBIT de N/A
- Akari Therapeutics Plc a EV/EBIT de N/A
- Youngevity International Inc a EV/EBIT de N/A
- Sigma Labs Inc a EV/EBIT de N/A
- GOLO Mobile a EV/EBIT de N/A
- NeuroOne Medical Technologies a EV/EBIT de N/A
- Vision Marine Technologies a EV/EBIT de N/A
- Medicenna Therapeutics a EV/EBIT de N/A